If you have been reading about DMSO stock and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-25. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
NADPH deficiency can cause a dysfunction in glutathione peroxidase which is an enzyme that converts hydrogen peroxide (a reactive oxygen species) into water. G6PD (glucose-6-phosphate dehydrogenase) deficiency exacerbated by administration of oxidant drugs (e.g., primaquine, dapsone, quinidine) can also result in Heinz bodies. G6PD deficient red cells in combination with high levels of oxidants causes a cross-linking of sulfhydryl groups on globin chains which causes a denaturing and formation of Heinz body precipitates. Heinz bodies can also be found in chronic liver disease. Alpha-thalassemia. Normal adult hemoglobin is composed of two alpha and two beta chains. Alpha thalassemia patients have partial or complete defects in alpha globin production, leading to a relative abundance of beta globin chains in the cell. These excess beta globin chains aggregate to form HbH, which has decreased solubility and precipitates in the red blood cell cytoplasm. This is not direct damage to hemoglobin per se, but rather a perturbation in the quaternary structure of hemoglobin. The presence of Heinz bodies may also be a feature of hyposplenism or asplenia, when a damaged or absent spleen cannot remove these damaged cells from circulation.
A third‑generation Kamiokande detector, Hyper‑Kamiokande, is currently under construction and it will be about 5.2 times more massive than Super-Kamiokande (approximately 8 times larger in fiducial volume), designed to start data taking in 2028. It will achieve sensitivities 3–5 times better than Super-Kamiokande after 10 years of data taking. Other important experiments that will have competitive sensitivities in proton decay searches are JUNO in China (which started data taking in January 2026) and DUNE in the US (designed to start data taking in 2031). These three ambitious projects were originally proposed and funded primarily for neutrino‑oscillation studies, but they will nevertheless be able to probe proton decay with high sensitivity, as summarized in the following table.
When HypSys is silenced the production of protease inhibitors induced by wounding is halved compared to wild type plants indicating that both systemin and HypSys are required for a strong defence response against herbivores in tomato. When applied through cut petioles in Petunia, HypSys did not induce the production of protease inhibitors, but instead increased expression of defensin, a gene which produces a protein that inserts into microbial membranes, forming a pore. Defensin expression is also induced by AtPEP1. Tomato plants over-expressing systemin produced more volatile organic compounds (VOCs) than normal plants and parasitoid wasps found them more attractive. Systemin also upregulates the expression of genes involved in the production of biologically active VOCs. Such a response is crucial if antinutritional defences are to be effective, since without predators, developing insects would consume more plant material while completing their development. It is likely that VOC production is upregulated through different pathways, including oxylipin pathway that synthesises jasmonic acid aldehydes and alcohols that function in wound healing. Different AtPeps may allow A. thaliana to distinguish between different pathogens. When inoculated with a fungus, oomycete and a bacterium, the increases in AtPep expression varied depending on the pathogen. A. thaliana overexpressing AtProPep1 was more resistant to the oomycete Phythium irregulare.
Sources: en.wikipedia.org
Artificial nucleic acid analogues have been designed and synthesized. They include peptide nucleic acid, morpholino- and locked nucleic acid, glycol nucleic acid, and threose nucleic acid. Each of these is distinguished from naturally occurring DNA or RNA by changes to the backbone of the molecules.
He also wrote the music and the lyrics to "Hate to Feel", "Angry Chair" and "Head Creeps", and melodies to other songs. Staley's lyrics are largely viewed as having dealt with his personal troubles, such as drug use and depression. Staley also played guitar on "Angry Chair" and "Hate to Feel". Cantrell said of "Angry Chair" on the liner notes of the 1999 Music Bank box set:
Most dwarf gouramis live for about four to six years; with proper care, they can live longer. Dwarf gouramis are generally peaceful, but can be slightly territorial. They do well in most community aquariums. Temperatures of 27 °C (81 °F) are easily tolerated. Dwarf gouramis raised for aquarium trade in Singapore may carry dwarf gourami iridovirus. Recent research has shown that 22% of Singapore Trichogaster lalius carry this virus. Dwarf gouramis are often confused with the closely related thick-lipped gouramis at a younger age and are sometimes sold together.
Sources: en.wikipedia.org
Seaborg was notified and the team left to sleep. Additional analysis and further experimentation showed the produced mendelevium isotope to have the expected mass of 256 and decay by electron capture to fermium-256 (half-life 157.6 minutes), the source of the observed fission.
Dennis Richard Abercrombie Matheson. Chair, Tenant Farmers Association Cymru. For services to the Tenanted Agricultural Sector in Wales. Zamanganga Mbatha. Head of Profound and Multiple Learning Disabilities, Royal Docks Academy. For services to Teenagers with Learning Difficulties in the London Borough of Newham. Hugh McAninch. Lately Regional Coordinator, The Compassionate Friends. For services to Bereaved Families in Scotland. Elizabeth McCrory. Regional Lead, UK Export Finance. For services to Exporting Businesses in Northern Ireland. Gordon Stirling McIntyre. Founder and Chair, Hospitality Health. For services to the Tourism and Hospitality Industry in Scotland. Gwyneth Kathleen McKenzie. Team District Commissioner, Hadrian District, Scout Association. For services to Young People and to the community in Northumberland, North Tyneside and Newcastle upon Tyne. James Ian McLean. Deputy Chief Nurse, Programme Delivery, Health Education England. For services to Nursing. Robert William McVeigh. For services to the Commonwealth Games in Northern Ireland. Donna Elaine McWilliams. Deputy Group Co-ordinator, Stepping Stones Play and Learn. For services to Early Years and Special Needs Education. Marion Anne Meakin. Senior Probation Officer, North West Probation Service, HM Prison and Probation Service. For services to Reducing Reoffending and Public Protection. Christiana Melam, Chief Executive, National Association of Link Workers. For services to Social Prescribing. Mohammed Gulam Moula Miah. Chairman, Rajnagar Business Group and Moula Foundation.
Labcorp was an early pioneer of genomic testing using polymerase chain reaction (PCR) technology at its Center for Molecular Biology and Pathology in Research Triangle Park, North Carolina, where it also performs other molecular diagnostics. Labcorp operates the National Genetics Institute, Inc. (NGI), in Los Angeles, California, which develops PCR testing methods.
The central dogma of molecular biology deals with the flow of genetic information within a biological system. It is often stated as "DNA makes RNA, and RNA makes protein", although this is not its original meaning. It was first stated by Francis Crick in 1957, then published in 1958:
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.